is a worldwide leader in medical imaging.
Who is Lantheus?
Lantheus Medical Imaging is a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents. For more than 55 years, Lantheus has been dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The company’s proven success in discovering, developing and commercializing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough tools for the diagnosis and management of disease.
Lantheus imaging products include DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, the leading ultrasound contrast agent used in ultrasound exams of the heart, also known as echocardiographic exams; ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease; Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), a cardiac imaging agent that is the most successful radiopharmaceutical ever introduced and; TechneLite® (Technetium Tc99m Generator).
Lantheus has approximately 550 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia.
To be the leading provider of innovative medical imaging solutions to improve human life.
We create and provide pioneering medical imaging solutions to improve treatment of human disease.
A Proud Heritage
For more than half a century, Lantheus Medical Imaging, Inc. has helped physicians enhance patient care with its pioneering product portfolio that illuminates the heart and other organs. Formed in 1956 as New England Nuclear Corporation (NEN), the company grew to become a leader in the field of diagnostic imaging. In 1981, the company was purchased by E.I. du Pont de Nemours and Company. Bristol-Myers Squibb Company (BMS) subsequently acquired the diagnostic medical imaging business as part of its acquisition of DuPont Pharmaceuticals in 2001. In 2008, BMS Medical Imaging was acquired by Avista Capital Partners and formally re-launched as Lantheus Medical Imaging, operating again as an independent company.
DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
full Prescribing Information including boxed WARNING regarding serious cardiopulmonary reactions (PDF)
ABLAVAR® (gadofosveset trisodium) full Prescribing Information including boxed WARNING regarding Nephrogenic Systemic Fibrosis (NSF) (PDF)
TechneLite® Technetium Tc99m Generator full Prescribing Information (PDF)
Cardiolite® Kit for the Preparation of Technetium Tc99m Sestamibi for Injection full Prescribing Information (PDF)